Paradiem LLC Reduces Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Paradiem LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 41.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,486 shares of the medical research company's stock after selling 7,981 shares during the period. Paradiem LLC's holdings in IQVIA were worth $2,658,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. AMF Tjanstepension AB purchased a new stake in IQVIA during the 3rd quarter valued at about $148,096,000. Eagle Asset Management Inc. purchased a new stake in IQVIA during the 3rd quarter valued at about $102,982,000. iA Global Asset Management Inc. grew its stake in IQVIA by 1,225.3% during the 3rd quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company's stock valued at $63,013,000 after acquiring an additional 296,105 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in IQVIA by 2,765.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company's stock valued at $53,381,000 after acquiring an additional 261,848 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its stake in IQVIA by 33.4% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,039,436 shares of the medical research company's stock valued at $240,505,000 after acquiring an additional 260,271 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insiders Place Their Bets

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares of the company's stock, valued at approximately $1,313,642.67. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock worth $10,331,003 in the last ninety days. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Up 0.4 %

IQVIA stock traded up $0.90 during mid-day trading on Friday, reaching $234.88. 697,640 shares of the company's stock were exchanged, compared to its average volume of 761,918. The company has a market cap of $42.63 billion, a P/E ratio of 32.22, a P/E/G ratio of 2.27 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The company has a fifty day moving average of $245.28 and a 200-day moving average of $223.30.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm's quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the business earned $2.54 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IQV. Robert W. Baird boosted their target price on shares of IQVIA from $226.00 to $251.00 and gave the company a "neutral" rating in a report on Thursday, February 15th. Truist Financial boosted their target price on shares of IQVIA from $286.00 to $297.00 and gave the company a "buy" rating in a report on Tuesday, February 27th. UBS Group boosted their target price on shares of IQVIA from $240.00 to $300.00 and gave the company a "buy" rating in a report on Thursday, February 15th. Barclays boosted their target price on shares of IQVIA from $260.00 to $265.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. Finally, StockNews.com upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a report on Friday, February 16th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and a consensus target price of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.